«Grindeks» is the leading pharmaceutical company in the Baltic states. Main fields of action are research, development, manufacturing and sales of original products Mildronate® and Ftorafur®, more than 100 effective and safe generics and 16 kinds of active pharmaceutical ingredients. «Grindeks» specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups.

«Grindeks» Group consists of 4 subsidiary companies in Latvia, Estonia and Russia, but representative offices are opened in 10 countries.

Products are exported to 50 countries, export comprises 95% of the total turnover. The main markets are the Baltic States, Russia and other CIS countries, Germany, the Netherlands, Japan.

«Grindeks» shares are listed on the Official List of "NASDAQ OMX Riga".